The subcellullar localization of the platelet membrane receptors glycoproteins (GP) Ib and Ilb/lla has been studied within resting platelets by a combination of biochemical and cytochemical techniques. While both GPlb and GPllb/llla are localized within the plasma membrane and surface-connected canalicular system (SCCS) membranes, only GPIIb/ llla is present within the internal face of a-granular membranes. Previous studies demonstrated that plasmin can induce platelet stimulation and also decrease ristocetininduced platelet aggregation; it was suggested that this was because of GPlb degradation by plasmin. In this study, the respective localizations of both GPlb and GPllb/llla were visualized during in vitro plasmin stimulation of platelets. Generally, plasmin induced shape change, pseudopod formation, organelle centralization either with or without a-granule release depending on the conditions of stimulation. Plasmin treatment of platelets at 37°C resulted in the disappearance of GPlb from the cell surface and its subsequent redistribu-
LYCOPROTEIN (GP) Ib plays an essential role in
G primary hemostasis by serving as the surface receptor that attaches platelets to exposed subendothelium. This interaction is mediated by a plasma component, von Willebrand factor (vWF) present in the subendothelial matrix.'.' In resting platelets GPIb is randomly distributed on the cell surface. It has an apparent molecular weight (Mw) of 170 Kd and consists of two disulfide-linked subunits GPIba (Mw: 143 Kd) whose glycosylated part is named glycocalicin and GPIbP (Mw: 22 Kd); on average there are 25,000 molecules per latel let.^,^ In the platelet membrane, GPIb is complexed in a 1:l ratio with another membrane glycoprotein, GPIX.4.' The receptor for vWF lies on the terminal portion of the GPIba chain because a loss in the capacity of GPIb to bind vWF parallels the release of a 45-Kd glycopeptide during prote~lysis.~, ' Plasmin, a fibrinolytic enzyme, has been shown to activate platelets.8-'" It also induces a decrease in ristocetininduced platelet agglutination caused by a decrease in GPIb exposed on platelet membrane. It was assumed that degradation of GPIb has occurred."" In this study we have used an immuno-electron microscopic approach to follow the surface and intracellular distribution of GPIb during platelet stimulation by plasmin, and compared its localization with another membrane glycoprotein, GPIIb/IIIa, which is also present on the platelet membrane as well as in the a-gran~les.~~." GPIb was shown to be internalized rather than degraded during stimulation and this migration could be inhibited by actin disrupting agents.
MATERIALS AND METHODS

Platelets
Venous blood was collected into plastic tubes containing ACD buffer (6.8 mmol/L citric acid, 11.2 mmol/L trisodium citrate, 24 mmol/L glucose). The platelet-rich plasma (PRP) was obtained by centrifugation at 180g for 10 minutes at room temperature. The isolated platelets were obtained by further centrifugation of PRP at 1,100g for 10 minutes at room temperature and washed three times with the washing buffer (36 mmol/L citric acid, 5 mmol/L KCI, 2 mmoliL Ca CI,, 1 mmol/L MgCI,, 103 mmol/L NaCl, 5 mmoliL glucose, pH 7.4) containing 3.5 mdmL bovine albumin (Sigma Chemical Co, St Louis, MO), 7 ng/mL prostaglandin E, (Sigma), and 25 pg/mL apyrase (Sigma). The washed platelets were resuspended in Tyrode's buffer, containing 2.9 mmoliL Ca CI,. Washed platelets were exposed to 0.2 C U h L plasmin (Kabi Laboratory, Stockholm, Sweden) or buffer for control at 37°C or at 22°C for 5 minutes, conditions that were associated to a decrease in ristocetin-induced platelet agglutination." The reaction was performed with or without cytochalasin D 25 nmolil (Sigma).
Electron Microscopy
The reaction was stopped and the platelets fixed by 1% glutaraldehyde in Tyrode buffer, washed three times with Phosphate buffer 0.1 moliL pH 7.4 and embedded in glycol methacrylate for immunoelectron microscopy. Immunostaining for GPIb and GPIIbi IIIa was performed on thin sections as described previously." The anti-GPIb antibody was raised against GPIb IX complex and affinity purified against glycocalicin to render it a chain specific. The preparation of the anti-GPIIbiIIIa antibody was described previously." The electron dense probe was goat antirabbit IgG coupled to 10 nm colloidal gold (Janssen Laboratories, Beerse, Belgium). The sections were observed on a Philips 301 or CM 10 electron microscope.
Biochemical Study
The amount of platelet glycocalicin was measured before and after plasmin treatment, both in cell lysates and supernatants. The release of platelet glycocalicin was measured in the supernatant of plasmin-treated platelets. Glycocalicin was expressed in percent of total glycocalicin platelet content of control autologous platelet lysate.
Preparation of Platelets Lysate
Washed platelets were incubated for 30 minutes at 37°C with 1% Triton Xl00 in 0.05 m o l t Tris, 0.1 mol/L glycine and 5 mmol/L calcium chloride, pH 8.7, and then centrifuged at 100,OOOg for 45 minutes. As suggested by George and Torres,'" solubilization in the presence of calcium at 37°C was performed to allow the activation of the endogenous calcium-dependent protease, which hydrolyses actin-binding protein to release GPIb from the triton-insoluble cytoskeleton.
Preparation of the Plasmin-Treated Platelets Supernatants
Washed platelets, 5 x l@/mL were incubated at 37°C for 6 minutes with 0.2 CUlmL plasmin. After incubation plasmin action was stopped by aprotinin addition (50 p,mol/L) (Bayer Pharma, Puteaux, France), and then immediately centrifuged as above.
Glycocalicin was also determined in the plasmin-treated platelets. After incubation with plasmin the platelet pellets were washed twice to remove trapped released GPlb and then the pellets were solubilized as described above. The results are expressed as a percentage of solubilized untreated platelets.
Glycocalicin Enzyme-Linked Immunosorbent Assay (ELISA) Assay
ELISA microplates were firstly coated with 200 p,L of 10 pg/mL of IgG isolated from rabbit antiserum antihuman glycocalicin in 0.05 mol/L bicarbonate buffer, pH 9.5 for 2 hours at 37°C. Two hundred microliters of diluted samples in dilution buffer (15) (Tyrode buffer containing 0.05% tween and 1% bovine serum albumin) were incubated with coated wells for 2 hours at 37°C. Immunoadsorbed glycocalicin was assayed with biotinylated SZ-2 monoclonal antibody (MoAb) against GPlb (Immunotech, Marseille, France) used at 2 p,g/mL in dilution buffer. After 2 hours of incubation with biotinylated SZ-2, the plates were washed three times and then incubated for another 2 hours with peroxidasestreptavidin (Amersham, UK) diluted 1/500 in dilution buffer. After three washes, peroxidase bound to the plates was quantified with 0-phenylene diamine.
In these conditions a linear standard curve was established from control untreated platelet lysate between 5 x lO'platelets/mL. The ELISA method used for this study had a sensitivity that allowed the detection of the amount of glycocalicin contained in 5 x lo' platelets/mLglycocalicin from samples containing 5 x 1@ platelets/ mL. Thus, the threshold of detection is 0.1% of total glycocalicin.
Electrophoretic Blotting
The supernatants and platelet lysates from 5 x 108 platelets/mL prepared as described for ELISA test were electrophoresed under nonreduced condition on a 6.5% acrylamide gel and transferred electrically to a nitrocellulose sheet. The binding to the blot of the primary polyclonal antiglycocalicin antibody was detected with '%labeled protein A.
RESULTS
lmmunoelectron Microscopy
Resting Platelets
On resting platelets, GPIb immunolabeling was mainly found on the outside face of the plasma membrane where the larger part of the molecule is localized. The channels of the surface-connected canalicular system (SCCS) appeared to be more weakly labeled, gold particles being often distributed as clusters. Other platelet organelles displayed no labeling, including a-granules and mitochondria (Fig. 1) GPIIb/IIIa had the same distribution on resting platelet membranes as GPIb, and was also present on the a-granule membrane, outlining their inner wall, as described earlier" (Fig 2) .
Plasmin-Stimulated Platelets
After treatment with plasmin at 37"C, the platelets changed shape, with emission of pseudopods and organelle centralization. GPIb immunolabeling disappeared from the cell surface but was found in the prominent channels of the SCCS (Fig 3) .
When degranulation had occurred, mainly when platelets were treated by plasmin at low temperature (22°C) as described previously," GPIb was also found to be absent from the plasma membrane and to be redistributed into the channels from the SCCS. It was virtually absent from the limiting membrane in the area of granule fusion, formed mainly by the a-granule membranenq (Fig 4) .
As a control for the immunogold staining technique, after platelet stimulation by plasmin at 37°C
GPIb.
GPIIbIIIIa. GPIIbnIIa immunolabeling remained unchanged on the plasma membrane. It was still scant in the SCCS and unchanged on the a-granule membrane. However, platelets had undergone shape change and organelle centralization (Fig 5) .
GPIIblIIIa.
When a-granule release had occurred the expression of GPIIb/IIIa on the plasma membrane was much increased in contrast to the one of GPIb and was also intense on the limiting wall of degranulation ponds, where a-granules had fused. Superficial channels of SCCS were still poorly labeled (Fig 6) .
Plasmin and Cytochalasin D
Finally, when cytochalasin D, which is known to disrupt the polymerization of actin filaments:" was applied to platelets before plasmin stimulation (either at 37°C or 22°C) migration of GPIb was impaired and no internalisation of GPIb was observed; the labelling for GPIb remained : . virtually unchanged at the surface of the plasma membrane. Platelet shape change was also blocked by cytochalasin D (Fig 7) .
This last experiment led to the conclusion that only minimal degradation of GPIb was enhanced by plasmin.
Biochemical Study
Elisa assay showed only a small amount of released gycocalicin when platelets were exposed to plasmin for a short time (Table 1) . Most of the GPIb remained associated with platelets. Similar result was obtained with immunoblotting method. A time-dependent release of glycocalicin in the supernatants was observed. However, this release was not severe enough to cause a substantial decrease in the amount of platelet-associated GPIb (Fig 8) . The amount of glycocalicin released in the medium after plasmin action on platelets was only minimal (less than 3% of total) and not different from control samples, confirming that no degradation of GPlb had occurred before the bulk of GPlb being moved to the open canalicular system. These percentages are expressed in comparison with the initial total glycocalicin content of untreated patients. N = 4.
DISCUSSION
GPIb binding to vWF associated with exposed subendothelium is a major step in platlet adhesion. This function is reflected in vitro by vWF-mediated platelet agglutination. GPIb has previously been reported to be sensitive to degradation by several proteinases."*."-" Indeed, in vivo studies indicated that GPIb function was impaired during thrombolytic therapy and that this impairment was caused by degradation of GPIb by generation of plasmin." In this report, we present evidence that the defective agglutination of plasmin-treated platelets in the presence of vWF is not related to GPIb cleavage, because less than 3% of total glycocalicin was found in the supernatant of plasmin treated platelets, but to a redistribution of GPIb, which moves from the external membrane into the SCCS, preventing its interaction with plasma vWF. Indeed, platelet agglutination is mediated by surface-associated GPIb, but the intracellular pool would be ineffective for cellular interaction. This phenomenon is related to platelet structural 7 2 3 4 5 6 7 B Fig. 8 . lmmunoblot of GPlb in platelets lysates and in supernatants before and after plasmin treatment. The autoradiogram was exposed for 7 hours. Thirty microliters of platelet lysate or supernatant from 5 x 10' p l a t e l e t s h l were electrophoresed, and detected with polyclonal anti-glycocalicin antibody. Lane 1, control platelet lysate. GPIb is a transmembrane GP attached to actin-binding protein that connects GPIb to submembrane actin filaments." The polymerization of actin filaments has been found to regulate the platelet shape changes and platelet glycoprotein functions in response to stimuli. We have shown that the translocation of GPIb from the external membrane into the channels of the SCCS is related to actin polymerization. Cytochalasin D, a specific inhibitor of actin polymerization, inhibits ultrastructural modification induced by plasmin, such as shape change and centralization of granules. We have now demonstrated that cytochalasin D inhibits the migration of GPIb after plasmin stimulation. This redistribution of GPIb can be compared with the redistribution of the protein, talin, after platelet stimulation." Indeed, in our observation, in the presence of cytochalasin D immunolabeling for GPIb remains unchanged on the plasma membrane after plasmin treatment. In the work of Adelman et all' degradation of GPIb was observed after longer incubation with plasmin (up to 90 minutes), where endogenous proteases could be responsible for proteolysis. Indeed, in our work we only studied a short time of stimulation, ie, 6 minutes, when vWFmediated agglutination of platelets is initially decreased. Under these conditions, platelet lysis is unlikely, as demonstrated by morphologic examination. These authors described the release of a glycocalicin-like glycopeptide. However, for our immunocytochemical study, we used an antibody affinity-purified against glycocalicin, and, indeed, we could demonstrate the apparition of an intracellular pool of GPIb (glycocalicin) after plasmin stimulation. A reduction in external GPIb was also observed after stimulation of platelets by thrombin.'8~22 In this case, we (personal observation) and othersz3 could observe that the reduction in GPIb expression of platelet surface after thrombin stimulation was also mainly caused by intracellular translocation. In parallel, no removal of GPIIb/IIIa from the plasma membrane to the SCCS was observed on spread and suspended platelet^.'^.'^ We propose that a shift of platelet reactivity from GPIb-vWF-mediated initial contact with the vessel wall to GPIIbiIIIa-mediated aggregation is a physiological process during platelet-mediated hemostasis. Moreover, in vivo, the reduction of platelet surface GPIb may contribute to some extent to the prevention of local platelet adhesion to exposed subendothelium during fibrinolysis. This reduction may also have a beneficial role in preventing hydrolysis of GPIb by generated plasmin.
